Showing 2771-2780 of 5771 results for "".
- Gore Launches 0.5 mL Silicone-Free Gore Improject Plunger for Ophthalmic Pre-Filled Syringeshttps://modernod.com/news/gore-launches-05-ml-silicone-free-gore-improject-plunger-for-ophthalmic-pre-filled-syringes/2482843/W. L. Gore & Associates announced the commercial launch of the 0.5 mL silicone-free Gore Improject syringe plunger. The new offering, made within the company's PharmBIO business, is designed for prefilled syringes used in various applications, including ophthalmic intr
- Harrow Acquires US Commercial Rights to Byqlovi for Postoperative Inflammation and Painhttps://modernod.com/news/harrow-acquires-us-commercial-rights-to-byqlovi-for-postoperative-inflammation-and-pain/2482841/Harrow and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement in which Harrow has acquired the exclusive US commercial rights for Byqlovi (clobetasol propionate ophthalmic suspension) 0.05%. Financial terms of the deal were not d
- Zeiss Clarus 700 Receives NMPA Approval in Chinahttps://modernod.com/news/zeiss-clarus-700-receives-nmpa-approval-in-china/2482840/Zeiss Medical Technology announced that the Clarus 700 has received National Medical Products Administration (NMPA) approval in China. According to Zeiss, the Clarus 700 offers advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in true c
- EyeCare4Kids Names Maggie Cline as New CEOhttps://modernod.com/news/eyecare4kids-names-maggie-cline-as-new-ceo/2482838/The non-profit EyeCare4Kids announced the promotion of Maggie Cline, MPH, to Chief Executive Officer (CEO). Ms. Cline joined EyeCare4Kids in 2022 and served as Executive Director Utah, where she oversaw the delivery of more than 50,000 vision services annually at school clinics, community centers
- Navigate Patient Solutions Adds Ophthalmology Leaders to its Medical Advisory Boardhttps://modernod.com/news/navigate-patient-solutions-adds-ophthalmology-leaders-to-its-medical-advisory-board/2482835/Navigate Patient Solutions announced the addition of Vance Thompson, MD; David Cox, and Matthew P. Jensen to its Medical Advisory Board. Navigate is developing a patient engagement solution for ophthalmology. The startup partners with ophthal
- Bausch + Lomb Launches Blink Nourish and Blink Boost Lubricating Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-blink-nourish-and-blink-boost-lubricating-eye-drops-in-the-us/2482834/Bausch + Lomb announced the US launch of Blink Nourish and Blink Boost lubricating eye drops. According to B+L, both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry e
- FDA Accepts Tenpoint's New Drug Application for Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/fda-accepts-tenpoints-new-drug-application-for-brimochol-pf-for-the-treatment-of-presbyopia/2482832/Tenpoint Therapeutics announced that the FDA has accepted the new drug application (NDA) for Brimochol PF for the treatment of presbyopia. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026. The FDA noted that it is not planning to hold an advisory co
- Rare Pediatric Disease Designation Granted for Ocugen's Gene Therapy for the Treatment of Stargardt Diseasehttps://modernod.com/news/rare-pediatric-disease-designation-granted-for-ocugens-gene-therapy-for-the-treatment-of-stargardt-disease/2482831/Ocugen announced that the FDA has granted Rare Pediatric Disease Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. Previously, OCU410ST received Orphan Drug designations
- iVeena Submits IND Application to the FDA for Phase 2 Clinical Trial for Pediatric Myopiahttps://modernod.com/news/iveena-submits-ind-application-to-the-fda-for-phase-2-clinical-trial-for-pediatric-myopia/2482830/iVeena Delivery Systems announced the submission of an investigational new drug (IND) application to the FDA for IVMED-85 for the treatment of pediatric myopia. IVMED-85 is a new chemical entity (NCE), p
- SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patientshttps://modernod.com/news/spyglass-pharma-raises-75-million-series-d-funding-to-advance-its-long-term-drug-delivery-platform-for-glaucoma-patients/2482829/SpyGlass Pharma announced the closing of a $75 million Series D financing round to support the development of its drug delivery platform aimed at transforming the long-term treatment of glaucoma and other chronic eye diseases.